Actinogen Medical Limited (ASX:ACWOC)

Market Cap	98.44M +34.4%
Revenue (ttm)	5.49M -44.7%
Net Income	-14.73M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,152,107
Average Volume	305,580
Open	0.0190
Previous Close	n/a
Day's Range	0.0190 - 0.0190
52-Week Range	0.0070 - 0.0340
Beta	n/a
RSI	36.79
Earnings Date	Nov 23, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 6
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACWOC